Table 3 Response to treatment by treatment response score subgroups in the three clinical trials
Trial | Score group | Number of patients (%) | Cumulative probability of 2-year EDSS progression | Treatment effect | ||||
|---|---|---|---|---|---|---|---|---|
Total | Placebo | Laquinimod | Placebo | Laquinimod | HR (95% CI) | p* | ||
ALLEGRO N = 1101 | NR | 426 (38.7) | 219 (51.4) | 207 (48.6) | 6.30 | 8.87 | 1.31 (0.77–2.25) | 0.0007 |
R | 675 (61.3) | 336 (49.8) | 339 (50.2) | 10.74 | 4.03 | 0.38 (0.23–0.62) | ||
BRAVO N = 881 | NR | 367 (41.7) | 181 (49.3) | 186 (50.7) | 7.09 | 8.81 | 1.24 (0.70–2.19) | 0.006 |
R | 514 (58.3) | 268 (52.1) | 246 (47.9) | 9.12 | 3.65 | 0.40 (0.22–0.73) | ||
CONCERTO N = 1456 | NR | 1015 (69.7) | 526 (51.8) | 489 (48.2) | 6.09 | 6.56 | 1.08 (0.74–1.58) | 0.033 |
R | 441 (30.3) | 211 (47.8) | 230 (52.2) | 5.62 | 2.47 | 0.44 (0.21–0.94) | ||